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Pediatric associations have been urged not to interact with and not to accept support
from commercial providers of breast milk substitutes (BMSs), based on the assumption
that such interaction would lead to diminished promotion and support of breastfeeding.
The leadership of seven European pediatric learned societies reviewed the issue and
share their position and policy conclusions here. We consider breastfeeding as the
best way of infant feeding and strongly encourage its active promotion, protection,
and support. We support the World Health Organization (WHO) Code of Marketing of
BMSs. Infant formula and follow-on formula for older infants should not be advertised
to families or the public, to avoid undermining breastfeeding. With consistently restricted
marketing of BMSs, families need counseling on infant feeding choices by well-informed
pediatricians. Current and trustworthy information is shared through congresses and
other medical education directed and supervised by independent pediatric organizations
or public bodies. Financial support from commercial organizations for congresses,
educational, and scientific activities of pediatric organizations is an acceptable option if
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scientific, ethical, societal, and legal standards are followed; any influence of commercial
organizations on the program is excluded, and transparency is ensured. Public–private
research collaborations for improving and evaluating pharmaceuticals, vaccines, medical
devices, dietetic products, and other products and services for children are actively
encouraged, provided they are guided by the goal of enhancing child health and are
performed following established high standards. We support increasing investment
of public funding for research aiming at promoting child health, as well as for
medical education.
Keywords: continuing medical education, infant nutrition, infant and young child feeding, public private sector
cooperation, privately sponsored programs
During the last couple of years, different groups have tried to
put increasing pressure on pediatric associations and demanded
that these should not interact with commercial providers
of nutritional products for infants and young children, and
they should not accept any support from such companies
for congresses, educational, or research activities. Some have
proposed that “pediatric associations should function without
the influence of commercial interests” (1). The underlying
implication is that interaction with, and acceptance of, support
by commercial enterprises, specifically dietetic companies, would
change the actions of pediatric organizations such as educational
activities and medical guidelines, and such interaction would
lead to diminished promotion and support of breastfeeding.
The leaderships of the European Academy of Pediatrics (EAP),
the European Society for Pediatric Gastroenterology, Hepatology
and Nutrition (ESPGHAN), the European Society for Pediatric
Infectious Diseases (ESPID), the European Society of Pediatric
and Neonatal Intensive Care (ESPNIC), the European Society for
Pediatric Nephrology (ESPN), the European Society for Pediatric
Research (ESPR), and the Pediatric Section of the European
Society of Emergency Medicine (EUSEM) have individually
and jointly reviewed and discussed these issues and came to
a consensus on related concepts and policies. The aim of this
position paper is to present our considerations and conclusions.
BACKGROUND
There is unanimous agreement that breastfeeding is the best way
of infant feeding. It provides optimal protection and support
for maternal and child health, including healthy child growth,
development, and long-term health (2, 3). We strongly endorse
proactive protection, promotion, and support of breastfeeding.
Although breastfeeding rates and duration have increased
considerably during the last few decades in many European
Abbreviations: BMS, breastmilk substitutes; EAP, European Academy of
Paediatric; EFSA, European Food Safety Authority; ESPGHAN, European Society
for Paediatric Gastroenterology, Hepatology and Nutrition; ESPID, European
Society for Paediatric Infectious Diseases; ESPNIC, European Society of Paediatric
and Neonatal Intensive Care; ESPN, European Society for Paediatric Nephrology;
ESPR, European Society for Paediatric Research; EUSEM, European Society
of Emergency Medicine, Paediatric Section; HCPs, Health Care Professionals;
MS, breastmilk substitutes; WHA, World Health Assembly; WHO, World
Health Organization.
countries, the current situation is not yet satisfactory, and
considerable further improvements are possible and needed
(4). Numerous factors may influence breastfeeding rates, for
example, availability of information and support for parents
and expectant parents, societal standards such as conditions of
parental leave from work, support for breastfeeding in public
and at the workplace, the practices of marketing breast milk
substitutes (BMSs), and many others (4–8). Pediatricians and
other health care professionals (HCPs) need to take responsibility
and play an active role, particularly in informing, encouraging,
and supporting parents and expecting parents.
In 1981 the World Health Assembly (WHA) adopted the
International Code of Marketing of Breast-milk Substitutes (“Code
of Marketing”) (9, 10). The global pediatric community is
a strong supporter of this Code and its goal to eliminate
improper practices of marketing of BMSs that may undermine
breastfeeding. Since 1981, the WHA adopted several subsequent
resolutions that refer to the Code of Marketing, including, in
2016, a resolution entitled “Ending inappropriate promotion of
foods for infants and young children” (11). The text of this
resolution states that the WHA” WELCOMES with appreciation
the technical guidance on ending the inappropriate promotion
of foods for infants and young children.” The chosen wording,
“WELCOMES with appreciation” reflects the fact that some
member states of the WHA raised reservations, and there
was no full consensus on the resolution. WHA resolutions
express opinions and may provide policy recommendations,
but they are not binding for member states who retain their
own responsibility for decision making on implementation
of recommendations.
The World Health Organization (WHO) published the
“Guidance on Ending the Inappropriate Promotion of Foods for
Infants and Young Children. Implementation Manual” in 2017
(12). This guidance document refers to commercially produced
foods marketed as suitable for feeding infants and children
from 6 up to 36 months of age, including follow-on formula,
the so-called “growing up milks” for toddlers, and commercial
complementary foods. The guidance considers as BMSs “any
milks (or products that could be used to replace milk, such as
fortified soy milk), in either liquid or powdered form, that are
specifically marketed for feeding infants and young children up
to the age of 3 years (including follow-up formula and growing-
up milks).” It further states, “Companies that market foods for
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infants and young children should not create conflicts of interest
in health facilities or throughout health systems.” Listed examples
of actions considered inappropriate include, i.e., provision of
free or reduced-price products considered BMSs through health
workers or health facilities; donation of equipment, services, or
gifts to health facilities, or HCPs; and sponsoring meetings of
HCPs and scientific meetings. The background text proposes that
the reputation and credibility of HCPs and their associations
would be damaged if funding is accepted “by a company that
makes a profit on goods that are not in the best interest of maternal
and child health” (12), and it implies that breast milk substitutes
generally would not serve the best interest of child health.
OUR POSITION
The conclusions presented here are based on extensive
professional experience, a nonsystematic review of current
literature, and detailed discussions within and among the
participating societies, and they present a consensus position on
concepts and policy.
We enthusiastically encourage effective protection,
promotion, and support of breastfeeding. This requires
active engagement of pediatricians and their collaborative action
with multiple stakeholders in numerous areas such as policy
and planning, parental leave, and other support of families,
information, education and communication, training of HCPs
and others, monitoring, and research (6). Improper marketing
practices of BMSs can adversely affect breastfeeding practice,
but the common assumption that marketing practices of BMSs
would be the dominant factor predicting breastfeeding practices
in Europe is not based on any accountable evidence. In fact, while
the regulations and practices of BMS marketing are comparable
in the European Union member states, breastfeeding rates and
duration vary markedly between member states (4), which
indicate that factors other than BMS marketing are of great
relevance here. However, we do support a ban on advertising
infant formula and follow-on formula for older infants to
families and the public to avoid the risk of undermining
breastfeeding. Infant formula and follow-on formula for older
infants serve as substitutes for human milk, and improper
marketing may mislead families to perceive formula feeding as
equivalent to breastfeeding (6). While current European Union
regulations restrict the marketing of infant formula, they do
not do this to the same extent for follow-on formula. This is
not satisfactory because follow-on formulas for older infants
are generally presented with similar brand names and design as
infant formulas. Therefore, advertising follow-on formulas can
lead to cross-marketing of infant formulas. Also, no marketing to
consumers should occur for foods for special medical purposes
for infants (e.g., special formula for treating cows’ milk allergy),
which should only be used upon medical advice.
The WHO guidance document also suggested to ban all
marketing for complementary foods and for formulas for
young children (12). The WHO has defined complementary
foods as all foods provided to infants other than human
milk, which thus includes also infant formula (13), motivated
by the goal to promote exclusive breastfeeding. In contrast,
pediatric organizations and government bodies in Europe, such
as the European Food Safety Authority, consider this definition
unhelpful and even confusing. Given that many infants receive
formula during the 1st year of life either alongside breastfeeding
or as the sole diet, in Europe, complementary foods are
generally defined as all solid and liquid foods provided to infants
other than breastmilk, or infant and follow-on formula (14–
17). From a pediatric perspective, homemade and commercial
complementary foods are meant to be provided alongside
breastfeeding and not as a replacement for breastfeeding, and
hence, these are not considered as BMSs. Likewise, formulas for
young children aged 1 year or older are meant to be offered
as an alternative to cows’ milk in a diversified diet to improve
nutrient provision, along with continued breastfeeding, but not
to replace breastfeeding. Therefore, complementary foods and
formulas for young children do not require the same marketing
restrictions as BMSs, provided there is no cross-promotion of
formulas, with presentation under different product names and
package designs. We see the risk that banning all information
regarding complementary foods and formulas for young children
may lead families to take uninformed inappropriate choices and
could induce a preferential use of low-quality products without
restricted advertising, such as soft drinks and junk foods. In the
current situation with a very high prevalence of childhood obesity
with its life-long adverse health consequences (18), this would be
a highly undesirable effect.
Implementation of effective restrictions of the marketing of
infant and follow-on formula to families and the public makes
it essential that families can obtain evidence-based counseling
on infant feeding choices from well-informed pediatricians
and other HCPs. Therefore, pediatricians and other HCPs
need access to evidence-based information on current scientific
knowledge, as well as information on available products.
Trusted information providers are learned pediatric societies
and professional organizations, and governmental bodies. They
share information with pediatricians and other HCPs through
congresses, different forms of continuing medical education
(CME), and other information channels. The essential role of
pediatric professional organizations in providing guidance for the
work of HCPs was again evident during the Covid-19 pandemic
(19, 20). Medical professional societies are best placed to provide
independent, unbiased, and effective CME.
We strongly disagree with the recently published position
of the European pharmaceutical industry association taking
the view that commercial enterprises should independently
be organizing medical education activities (21). We maintain
that commercial enterprises must not direct and offer CME
activities for HCPs on their own because the existing conflicts
of interest make it highly unlikely that bias can be avoided
(22). Congresses and CME activities should therefore be
organized under the direction and supervision, and within
the regulatory framework of independent, nonprofit learned
societies, professional organizations, or governmental and public
bodies. The organizing bodies should follow core values
such as humanity, integrity, quality, independence, respect,
accountability, and transparency, ensure that programs and their
Frontiers in Pediatrics | www.frontiersin.org 3 November 2020 | Volume 8 | Article 562870
Bognar et al. Promoting Breastfeeding and Interaction With Industry
contents are balanced and present evidence-based information,
and strictly exclude any influence of commercial interests on
the programs.
HCPs use commercial products and services in their work
and require related information, including information on
product properties from commercial providers, and they provide
feedback to commercial manufacturers on medical needs.
Therefore, a dialogue between HCPs and their organizations
with commercial providers is helpful and necessary. A recently
published survey reported that two thirds of pediatric
associations in Europe accepted exhibition participation or
other forms of support from commercial providers of BMSs
(1) along with a variety of other sources of support, given that
provision of quality information and CME requires considerable
resources and funding. The collaboration between medical
professional societies and commercial enterprises in congresses
and education involves inevitable challenges, but also important
opportunities (22). The mission, vision, and values of pediatric
organizations should guide decisions on their interaction with
commercial organizations, as expressed before by the American
Academy of Pediatrics (23). The “Code of Conduct for HCPs and
Scientific Organizations” adopted by the Biomedical Alliance
in Europe and the “Code for Interactions With Companies of
the American Council of Medical Specialty Societies” provide
examples for possible guiding principles that should be followed
(24). Pediatricians and other HCPs are aware that providers of
pharmaceuticals and vaccines, medical devices, dietetic products,
and other products and services, have commercial interests, and
they are generally able to critically evaluate communication from
commercial enterprises. We support the option of participation
of commercial enterprises in commercial exhibitions held at
medical meetings or their financial sponsorship for congresses,
educational events, and other forms of continuing medical
education (CME) for pediatricians and other HCPs under the
direction of independent medical professional societies, or
governmental and public bodies. However, event organizers
need to follow agreed scientific, ethical, and societal standards
(24), and ensure transparency and absence of any influence of
commercial enterprises on the program and content of activities.
We disagree with setting different rules and regulations for
accepting support from companies offering dietetic products
for infants and young children, compared to support from
commercial enterprises offering other products, medications,
and services for healthcare, considering that all commercial
companies may have relevant conflicts with the interests
of patients and the public that equally need to be carefully
monitored and addressed.
Banning financial support from some commercial
organizations, such as providers of BMSs, for activities of
pediatric societies and professional associations, without
an adequate replacement by public funding, would further
disadvantage the provision of pediatric healthcare, compared
to adult healthcare where such restrictions are not requested.
Realistically, the expected financial losses cannot be compensated
for by increased user fees or public funding. Therefore, it would
lead to a much-reduced offer of, and access to, evidence-based
information sharing to pediatricians and other HCPs, which they
require on a regular basis to optimally support child health in
their daily work. Moreover, the health policy of the European
Union and European countries (25) and of the WHO (26)
expressly encourage collaboration of all stakeholders in order to
maximize impact and benefit for people.
The United Nations Convention on the Rights of the Child
stipulates that children have the right to the highest attainable
standards of health and health care (27). Accordingly, children
deserve access to innovative, safe, and suitable pharmaceuticals,
vaccines, medical devices, dietetic products, and other products
and services that are appropriately evaluated. While we
enthusiastically support breastfeeding, we recognize that healthy
infants that are not (or not fully) breastfed need BMSs, and that
many sick infants require therapeutic dietetic products, both of
which should be of the highest achievable quality to support
child health and well-being. We strongly disagree with the view
expressed by the WHO that such products would generally be
“goods that are not in the best interest of child health” (12).
BMSs are needed for infants that are not breastfed for different
reasons to support their health as best as possible (10). BMSs or
supplements to breastfeeding can even be an essential medical
requirement for some infants with certain disorders, such as
those born very preterm and those with inherited metabolic
disorders, intestinal failure, complex food allergy, congenital
cardiac lesions, enterocolitic syndromes, severe gastroesophageal
reflux, neurodisability, and others (28, 29).
European regulations stipulate the need for evaluating the
safety and suitability of pharmaceuticals, medical devices, as well
as dietetic products for infants. Such evaluations usually require
clinical studies performed in public–private collaboration. We
encourage and support public–private research collaborations for
improving and evaluating health-related products and services
for children, provided these are guided by prioritizing the
goal of enhancing child health and are performed following
current scientific, ethical, and societal standards (30). At the
same time, we strongly recommend strengthening public funding
investment for research aiming at promoting child health, as well
as for CME, in the interest of all stakeholders.
CONCLUSIONS
• Breastfeeding is the best way of infant feeding. We strongly
encourage active promotion, protection, and support of
breastfeeding, in particular through active encouragement and
support by pediatricians and other HCPs.
• Breastfeeding rates and duration have increased during
the last few decades in many European countries,
but further improvements are needed and possible
through collaborative efforts of pediatricians and multiple
other stakeholders.
• Infant formula and follow-on formula for older infants
may serve as breast milk substitutes and should not be
advertised to families or the public, to avoid the risk of
undermining breastfeeding.
• Complementary foods for older infants and toddlers as well
as formulas for young children should be offered along with
continued breastfeeding, but not replace breastfeeding. They
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do not require the same strict marketing restrictions as BMSs
provided there is no cross-promotion of formulas for infants.
• Families need counseling on infant feeding choices by well-
informed pediatricians and other HCPs who have access to
current evidence.
• Pediatricians and other HCPs can obtain current information
through congresses and other forms of continuing medical
education that should be directed and supervised by
independent pediatric organizations, or public bodies.
Commercial enterprises should not direct and offer scientific
events and CME for HCPs to avoid any bias due to potential
conflicts of interest.
• Financial support from commercial enterprises for congresses,
CME activities, and other activities of learned societies
and professional organizations is an acceptable option if
agreed scientific, ethical, societal, and legal standards are
followed, which includes ensuring no influence of commercial
enterprises on the program, and content of activities and
transparency on financial support.
• Public–private research collaborations for improving and
evaluating pharmaceuticals, vaccines, medical devices, dietetic
products, and other products and services for children are
encouraged, provided they are guided by the goal of enhancing
child health and are performed following current ethical,
scientific, and societal standards.
• Investment of public funding for research aiming at promoting
child health, as well as for CME, should be strengthened.
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